News and Media

2015/09/22 – Quantum Genomics to meet investors at the European Large & Midcap Event, October 7 & 8, 2015

22 September 2015
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, will be participating at the 15th edition of the European Large & Midcap Event, a conference dedicated to meetings between European […]

2015/09/08 – Phase IIa clinical trial for high blood pressure : 50% enrolment four months ahead of schedule and Supervisory Board meeting coming up

8 September 2015
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces it has now recruited more than half the patients for its Phase IIa trial of its drug candidate QGC001. This […]

2015/08/24 – Disclosure of the total number of voting rights and the number of shares of the share capital

24 August 2015
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, has published information on the total number of voting rights and number of shares comprising the share capital on august 23rd […]

2015/07/27 – Quantum Genomics announces the appointment of Professor Faiez Zannad as its heart failure consultant

27 July 2015
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC)), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, is announcing its collaboration with Professor Faiez Zannad, acting as a specialized consultant, in order to accelerate its developments […]